Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Onconova Therapeutics, Inc. | tm2026436-1_8k.htm |
Exhibit 99.1
 |
By Electronic Delivery to: mguerin@onconova.us August 3, 2020 Mr. Mark Geurin Chief Financial Officer Onconova Therapeutics, Inc 375 Pheasant Run Newtown, PA 18940 Re: Onconova Therapeutics, Inc. (the “Company”) Nasdaq Symbol: ONTX Dear Mr. Geurin: On December 4, 2019, Staff notified the Company that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market. Since then, Staff has determined that for the last 10 consecutive business days, from July 20, 2020 to July 31, 2020, the closing bid price of the Company’s common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed. If you have any questions, please contact me at +1 301 978 8085. Sincerely, Patryk Muter Listing Analyst Nasdaq Listing Qualifications |